Growth and recovery prospects make these ten stocks look inexpensive below 20x forward earnings. SK hynix, Micron and Sandisk benefit from memory and storage demand; Vistra from electricity demand; Oracle and Nvidia from AI infrastructure; Nu from banking growth and Uber from cash generation. Novo Nordisk's improving execution could make 12x attractive despite pricing pressure. Onsemi's recovery could run further as AI power efficiency matters more. x.com  x.com  x.com  x.com  x.com  x.com  x.com  … Show more

Semiconductor and memory stocks still look cheap despite the panic on forward earnings and growth-adjusted valuations. SK hynix trades at 4.4x forward earnings with a 0.04 PEG, Micron at 4.6x and 0.11, Sandisk at 5.5x and 0.10, and Nvidia at 14.2x and 0.22; the table extends across chipmakers and suppliers. Some of these figures may reflect peak earnings. x.com  x.com 

Novo Nordisk's P/E is expected to rise because its earnings are expected to drop. The market is forward-looking, not backward-looking, and it doesn't like companies that have completely messed up for years, as Novo has. x.com 

Microsoft, ServiceNow, Netflix, Meta Platforms, S&P Global, Amazon, Fair Isaac and Novo Nordisk look like a great opportunity today as high-quality companies, on the view that over the long term a stock's valuation tracks its earnings growth, so price should follow EPS. x.com  x.com  x.com  x.com  x.com  x.com  x.com  x.com 

A four-year memory supply shortage could make low forward earnings multiples compelling if long-term agreements hold. At forward P/Es of 3.5 for Samsung, 5 for Micron and 3.1 for SK hynix, the sub-4 names could return roughly 100% over four years and still retain value even if margins subsequently compress sharply. x.com  x.com 

Micron, SK hynix and SanDisk look absurdly cheap, but the market refuses to pay more for their earnings because no one knows what sales or margins look like five years out. Today's roughly 5x earnings could prove ridiculously cheap, yet those earnings could just as easily fall until 5x becomes 20x. That raises the question of whether owning them is investment or speculation. x.com  x.com 

Novo Nordisk is cheap at about 9x earnings, even assuming zero earnings growth. At 15x its current earnings it would be worth about $61 a share, and at 20x about $82. That $82 level is roughly a return to the 200-week moving average, about 115% upside, so the fundamental rerating and the technical target point to the same area. x.com 

Novo Nordisk trades at its lowest valuation ever, about 7x earnings, in the same year it launched one of the most in-demand oral medications in the world. Competition from Eli Lilly is a real headwind, but even if Novo's oral market share fell to 50% it should do fine, and an expected 1-3% earnings drop next year hardly justifies 7x. Novo should still be competing at a similar scale in seven years. x.com  x.com  x.com  x.com  x.com 

SK hynix trades at about 3x next year's earnings once adjusted for cash build and equity stakes, with $200B+ of profit expected next year. If 2028 profit matches, its enterprise value would be $400B or less, under 2x 2029 earnings; even if pricing falls, a bad scenario is about 5x 2029 earnings. Per @wallstengine, Q2 operating margin hit a record 76% as revenue rose 257% year on year, though revenue and profit missed estimates. x.com 

SK hynix is still very cheap, even after the stock rose 734% over the past year. x.com